Regeneron has reached a $2.94 billion agreement with the federal government to supply more doses of its monoclonal antibody cocktail to treat COVID-19.
Under the new agreement with the U.S. Department of Health and Human Services and the Department of Defense, Regeneron will furnish another 1.4 million doses of the treatment by the end of January 2022.
The one-dose therapy will be made available to any member of the American public who is eligible to receive it. It currently is authorized to treat COVID-19 patients ages 12 and up who have mild to moderate symptoms and are at high risk of severe illness.
The deal comes as orders of monoclonal antibodies from states have gone up 1,200% in recent weeks during the delta surge, ABC News reported last month.
Click here to read more.